BIO: Upbeat Zevra Advances Promising Rare Disease Portfolio

With the urea cycle disorder treatment Olpruva launched and the NPC therapy arimoclomol closing in on US approval, Zevra is one to watch in the rare disease space.

Josh Schafer
Joshua Schafer • Source: Zevra

More from Strategy

More from Business